Summarized by Masters of Longevity from Longevity Technology.
Announcement that a Swedish biotech will present its central nervous system drug pipeline and recent partnership updates at a Zurich investor and partnering conference.
Key Takeaways
- The company will present its CNS pipeline and corporate update at Swiss Nordic Bio 2026 in Zurich.
- Recent collaboration and outlicensing agreements were signed with Eli Lilly and QuantumCell ApS relating to Alzheimer’s programs.
- The CEO will hold one-on-one meetings with investors and potential partners at an event featuring around 200 participants and 400 meetings.
